All Congress Publications
Boehringer Ingelheim is committed to sharing knowledge with the healthcare community. Follow the links and find a variety of downloadable resources and articles with information related to Oncology.
1 - 10 of 102 results
Publications
Gathering our presentations, posters, abstracts, and publications, this educational resource offers materials across topics of interest in oncology. Explore the current topics below and revisit regularly to access the latest materials.
Poster
Zongertinib in HER2-mutant advanced NSCLC: impact of therapy line on efficacy
Author(s): Wu et al.
DAREON®-7: Phase I open-label dose-escalation/-expansion study of first-line obrixtamig (BI 764532) plus platinum-doublet chemotherapy in patients with DLL3-positive neuroendocrine carcinomas
Author(s): Chauhan et al.
ctDNA analysis following zongertinib treatment in patients with HER2-mutant NSCLC: Phase Ia/Ib BeamionTM LUNG-1 study
Author(s): Heymach et al.
Beamion™ BCGC-1: A phase Ib/II, randomized, open-label, multicenter trial of oral zongertinib, alone or in combination, for the treatment of advanced HER2-positive metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC)
Author(s): Hurvitz et al.
Ezabenlimab (BI 754091) and induction mDCF (modified docetaxel, cisplatin, and 5-fluorouracil) followed by adaptive chemoradiotherapy in patients with stage III squamous cell anal carcinoma: final results of the Phase II INTERACT-ION study
Author(s): Kim et al.
An open-label, Phase Ib trial to assess the safety and efficacy of SIRPα monoclonal antibody BI 770371 in combination with pembrolizumab with or without cetuximab compared with pembrolizumab monotherapy for the first-line treatment of patients with head and neck squamous cell carcinoma (NCT06806852)
Author(s): Laban et al.
Obrixtamig (BI 764532) in patients with relapsed/refractory DLL3-high expressing extrapulmonary neuroendocrine carcinoma: trial in progress of the dose expansion part of the Phase II DAREON®-5 trial
Author(s): Pavel et al.
DAREON®-9, a Phase Ib open-label dose escalation and dose confirmation study of obrixtamig (BI 764532) plus topotecan in patients with advanced small cell lung cancer: updated results
Author(s): Wermke et al.
Zongertinib in Patients with Previously Treated HER2-Mutant NSCLC and Brain Metastases at Baseline: Beamion™ LUNG-1
Author(s): Ruiter et al.
Zongertinib in HER2-altered gastrointestinal cancers: preclinical activity and clinical findings from a Phase Ia study
Author(s): Yoh et al.